Trial Profile
Safety of nilotinib in patients with acute myeloid leukaemia: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2016
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 01 Aug 2016 New trial record
- 07 Jun 2016 Primary endpoint of heart failure has not been met, according to results presented at the at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology